USMLE Forum - Largest USMLE Community

1. Which of the following chemotherapeutic agents has least known myelosuppression?

A. Actinomycin D
B. Cyclophosphamide
C. Bleomycin
D. Docetaxel

2. ____________ is not an antineoplastic agent, which binds to reactive metabolite of IFEX or Cyclophosphamide without affecting antitumor activity.

A. Fluorouracil
B. Tamoxifen
C. L-Asparaginase
D. Mesna

3. Filgrastim is a:

A. synthetic antiestrogen used in the treatment of breast cancer.
B. anti-metabolite chemotherapeutic agent.
C. human recombinant granulocyte colony–stimulating factor (G-CSF)
D. nitrogen mustard.

4. Which of the following chemotherapeutic agents is a folate-antagonist antimetabolite?

A. Thioguanine
B. Fluorouracil
C. Mercaptopurine
D. Methotrexate

1C
2D
3C
4D

My sweet psycho, it's like a quiz from my yesterday's material. THank you, my Psycho.

Agree

Yes all are correct. C, D, C, D

Hello Lovetest and Maryam. You are welcome

2 more Qs and then we can call it quits

1. A drug used in a chemotherapy regimen works by complexing with iron and oxygen to promote DNA strand breaks. While on this drug, the patient must be monitored closely due to pulmonary side effects. In what phase of the cell cycle does this drug work?

A. G1
B. S
C. G2
D. M
E. This drug is not cell-cycle dependent

2. Resistance to which anticancer drug, used in leukemias, lymphomas, and breast cancer, is associated with increased production of dihydrofolate reductase?

A. Doxorubicin
B. Vinblastine
C. 6-MP
D. Cytarabine
E. Methotrexate

1:c

2: ? e??

1C
2E

C and E are correct

I posted Q 2 because I wanted to share what I learned that resistance to methotrexate develops when cancer cells upregulate the DHFR or alter the binding of methotrexate to DHFR.

Both are Kaplan Qs.

thanks psychmledr